研究目的:測定Carvedilol,第三代ß-抗拮劑對急性冠心症病患的心臟保護作用 方法:病患來自屏東寶建醫院心臟內科,研究組之病患在胸痛症狀後六小時內開始給予Carvedilol,在急性期及三個月後,心臟超音波追蹤記錄:左心室舒張末期容積,左心室收縮期末容積及左心室排出分數。 結果:三個月後之追蹤比較,經由Analysis of variance (ANOVA)得知,左心室排出分數(left ventricular ejection fraction,LVEF)研究組高於對照組,P值為0.0435(P<0.05) 有統計學上之意義,但兩組於左心室舒張期末容積(left ventricular end diastolic volume,LVEDV)方面,沒有統計學意義上之差別。 結論:於急性冠心症早期開始投予Carvedilol有減低心室重塑之效果。
Objective: The aim of this study was to determine the cardiac protective effects of carvedilol, a third generation beta-adrenergic blocker, in acute stage of acute coronary syndromes. Methods: Patients from Department of Cardiology, Pao Chien Hospital were recruited for this echocardiographic study. In the study group patients started with carvedilol 6 hours within chest pain attack. Echocardiography, measuring left ventricular end diastolic volume (LVEDV),left ventricular end systolic volume (LVESV),left ventricular ejection fraction (LVEF) were performed then and repeated after 3 months. Results: At 3 months, left ventricular ejection fraction was significantly rise in the carvedilol group (P=0.0435) (ANOVA). Left ventricular end diastolic volume was not statistically different between the two groups. Conclusions: Early administration of carvedilol in Acute Coronary Syndromes results in attenuation of left ventricular remodeling.